# Pearl Therapeutics, Inc. clinical trials: 42 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with Pearl Therapeutics, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Pearl Therapeutics, Inc.: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/pearl-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 30, 2017 | NCT03358147 | Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma | Pearl Therapeutics, Inc. | Phase 2/3 | Completed | Asthma | 1,077 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03358147) |
| October 17, 2017 | NCT03311373 | A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010 | Pearl Therapeutics, Inc. | Phase 1 | Completed | Chronic Obstructive Pulmonary Disease | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03311373) |
| August 25, 2017 | NCT03262012 | Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler® | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03262012) |
| August 22, 2017 | NCT03256552 | Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD | Pearl Therapeutics, Inc. | Phase 2 | Completed | Chronic Obstructive Pulmonary Disease | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03256552) |
| August 15, 2017 | NCT03250182 | A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose | Pearl Therapeutics, Inc. | Phase 1 | Completed | Chronic Obstructive Pulmonary Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03250182) |
| March 16, 2017 | NCT03081247 | To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Pearl Therapeutics, Inc. | Phase 3 | Withdrawn | Chronic Obstructive Pulmonary Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03081247) |
| March 9, 2017 | NCT03075267 | Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects | Pearl Therapeutics, Inc. | Phase 1 | Completed | Chronic Obstructive Pulmonary Disease | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03075267) |
| October 18, 2016 | NCT02937584 | A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD, Chronic Obstructive Pulmonary Disease | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02937584) |
| May 10, 2016 | NCT02766608 | Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in... | Pearl Therapeutics, Inc. | Phase 3 | Completed | Chronic Obstructive Pulmonary Disorder | 2,389 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02766608) |
| April 4, 2016 | NCT02727660 | A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate... | Pearl Therapeutics, Inc. | Phase 3 | Completed | Chronic Obstructive Pulmonary Disorder | 1,876 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02727660) |
| February 18, 2016 | NCT02685293 | Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD | Pearl Therapeutics, Inc. | Phase 3 | Terminated | COPD | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02685293) |
| December 30, 2015 | NCT02643082 | A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to... | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02643082) |
| September 1, 2015 | NCT02536508 | Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive... | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 627 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02536508) |
| July 14, 2015 | NCT02497001 | A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003... | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 1,902 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02497001) |
| June 8, 2015 | NCT02465567 | Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 8,588 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02465567) |
| May 27, 2015 | NCT02454959 | Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02454959) |
| May 5, 2015 | NCT02433834 | Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or... | Pearl Therapeutics, Inc. | Phase 2 | Completed | Asthma | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02433834) |
| January 27, 2015 | NCT02347085 | 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02347085) |
| January 27, 2015 | NCT02347072 | 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active... | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02347072) |
| January 22, 2015 | NCT02343458 | Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD | Pearl Therapeutics, Inc. | Phase 3 | Completed | Chronic Obstructive Pulmonary Disease | 1,756 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02343458) |
| October 20, 2014 | NCT02268396 | Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD | Pearl Therapeutics, Inc. | Phase 3 | Completed | COPD | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02268396) |
| July 23, 2014 | NCT02197975 | Randomized, Crossover Safety and Pharmacokinetics Study of PT010 | Pearl Therapeutics, Inc. | Phase 1 | Completed | COPD | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02197975) |
| July 22, 2014 | NCT02196714 | PK Study of PT003 and PT001 in Japanese Healthy Subjects | Pearl Therapeutics, Inc. | Phase 1 | Completed | COPD | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02196714) |
| July 21, 2014 | NCT02196077 | Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Pearl Therapeutics, Inc. | Phase 2 | Completed | Chronic Obstructive Pulmonary Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02196077) |
| July 14, 2014 | NCT02189304 | Pharmacokinetics and Safety Study of PT010 in Healthy Subjects | Pearl Therapeutics, Inc. | Phase 1 | Completed | COPD | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02189304) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 2 |
| Phase 2 | 13 |
| Phase 2/3 | 1 |
| Phase 3 | 18 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 39 |
| Withdrawn | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pulmonary Disease, Chronic Obstructive | 37 |
| Asthma | 3 |
| Lung Diseases, Obstructive | 1 |
| Lymphoma, Follicular | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Inns in the United States](https://specstream.ai/data/businesses/inns/united-states)
- [Appraisers in the United States](https://specstream.ai/data/businesses/appraisers/united-states)
- [Lodges in the United States](https://specstream.ai/data/businesses/lodges/united-states)
- [B2B water treatment companies in the United States](https://specstream.ai/data/businesses/b2b-water-treatment-companies/united-states)
- [Neuropathology practices in the United States](https://specstream.ai/data/businesses/neuropathology-practices/united-states)
